SCHEMBL16644672

SCHEMBL16644672

CCCCOc1ccccc1Oc1cc(C)cc2cc[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.40
CYP2C9 P11712 4/20 0.40
CYP2C19 P33261 4/20 0.40
L3MBTL1 Q9Y468 9/20 0.39
MAPT P10636 8/20 0.39
RAB9A P51151 5/20 0.39
ATM Q13315 1/20 0.39
PDE5A O76074 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HPGD P15428 6/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPK1 P28482 1/20 0.36
TLR8 Q9NR97 1/20 0.36
NPC1 O15118 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP19A1 P11511 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16644673 0.82 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT
SCHEMBL16632385 0.82 L3MBTL1 (0.44) L3MBTL1MAPTTDP1MAPK1SMN1; SMN2
SCHEMBL16632579 0.77 L3MBTL1 (0.41) L3MBTL1SMN1; SMN2KDM4E
SCHEMBL837183 0.76 BCHE (0.50) CYP1A2CYP2C9CYP2C19L3MBTL1PDE5A
SCHEMBL10730442 0.75 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT
SCHEMBL8578238 0.70 ACHE (0.45) MAPK1TLR8CYP3A4
1,2-Dibutoxybenzene SCHEMBL1226749 0.70 CYP1A2 (0.72) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT
1,2-Dibutoxybenzene SCHEMBL29428927 0.70 CYP1A2 (0.72) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT
SCHEMBL6933945 0.69 LMNA (0.57) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT
SCHEMBL16644669 0.68 HPGD (0.49) CYP1A2CYP2C9CYP2C19L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR CYP1A2 567/4885CYP2C9 1797/4885CYP2C19 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.